Inseego: Q1 Earnings Insights

Inseego (NASDAQ:INSG) reported its Q1 earnings results on Wednesday, May 3, 2023 at 04:01 PM. Here’s what investors…

Inseego (NASDAQ:INSG) reported its Q1 earnings results on Wednesday, May 3, 2023 at 04:01 PM.

Here’s what investors need to know about the announcement.

Earnings

Inseego beat estimated earnings by 75.0%, reporting an EPS of $-0.02 versus an estimate of $-0.08.

Revenue was down $10.59 million from the same period last year.

Past Earnings Performance

Last quarter the company missed on EPS by $0.02 which was followed by a 4.77% drop in the share price the next day.

Here’s a look at Inseego’s past performance:

Quarter Q4 2022 Q3 2022 Q2 2022 Q1 2022
EPS Estimate -0.09 -0.08 -0.11 -0.11
EPS Actual -0.11 -0.11 -0.09 -0.11
Revenue Estimate 60.53M 65.12M 62.37M 62.64M
Revenue Actual 52.91M 69.17M 61.86M 61.38M

To track all earnings releases for Inseego visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Recap: DexCom Q2 Earnings

DexCom (NASDAQ:DXCM) reported its Q2 earnings results on Thursday, July 28, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings DexCom missed estimated earnings by 10.53%, reporting an EPS of $0.17 versus an estimate of $0.19.

DXCM

Read More

Bristol Myers Squibb’s Stocks Falls on Q2 Miss, FY23 Forecast Cut As Two Of Its Top Drugs Face Generic Competition

Bristol Myers Squibb & Co (NYSE: BMY) said that its Q2 revenues of $11.23 billion declined 6% Y/Y, or 5% when adjusted for foreign exchange, due to lower sales of Revlimid, partially offset by in-line products and our new product portfolio.

BMY